GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Shares Outstanding (EOP)

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Shares Outstanding (EOP) : 667.16 Mil (As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Pathfinder Cell Therapy's shares outstanding for the quarter that ended in Sep. 2015 was 667.16 Mil.

Pathfinder Cell Therapy's quarterly shares outstanding stayed the same from Jun. 2015 (667.16 Mil) to Sep. 2015 (667.16 Mil).

Pathfinder Cell Therapy's annual shares outstanding declined from Dec. 2013 (667.16 Mil) to Dec. 2014 (667.16 Mil). It means Pathfinder Cell Therapy bought back shares from Dec. 2013 to Dec. 2014 .


Pathfinder Cell Therapy Shares Outstanding (EOP) Historical Data

The historical data trend for Pathfinder Cell Therapy's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy Shares Outstanding (EOP) Chart

Pathfinder Cell Therapy Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 110.18 667.16 667.16 667.16 667.16

Pathfinder Cell Therapy Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 667.16 667.16 667.16 667.16 667.16

Competitive Comparison of Pathfinder Cell Therapy's Shares Outstanding (EOP)

For the Biotechnology subindustry, Pathfinder Cell Therapy's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pathfinder Cell Therapy's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pathfinder Cell Therapy's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Pathfinder Cell Therapy's Shares Outstanding (EOP) falls into.



Pathfinder Cell Therapy Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Pathfinder Cell Therapy  (OTCPK:PFND) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Pathfinder Cell Therapy Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Traded in Other Exchanges
N/A
Address
12 Bow Street, Cambridge, MA, USA, 02138
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Executives
John J Alam director 130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines